Đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân hội chứng mạch vành cấp được can thiệp động mạch vành qua da tại Bệnh viện Đa khoa Trung ương Thái Nguyên (Luận văn thạc sĩ)

Đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân hội chứng mạch vành cấp được can thiệp động mạch vành qua da tại Bệnh viện Đa khoa Trung ương Thái Nguyên (Luận văn thạc sĩ)Đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân hội chứng mạch vành cấp được can thiệp động mạch vành qua da tại Bệnh viện Đa khoa Trung ương Thái Nguyên (Luận văn thạc sĩ)Đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân hội chứng mạch vành cấp được can thiệp động mạch vành qua da tại Bệnh viện Đa khoa Trung ương Thái Nguyên (Luận văn thạc sĩ)Đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân hội chứng mạch vành cấp được can thiệp động mạch vành qua da tại Bệnh viện Đa khoa Trung ương Thái Nguyên (Luận văn thạc sĩ)Đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân hội chứng mạch vành cấp được can thiệp động mạch vành qua da tại Bệnh viện Đa khoa Trung ương Thái Nguyên (Luận văn thạc sĩ)Đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân hội chứng mạch vành cấp được can thiệp động mạch vành qua da tại Bệnh viện Đa khoa Trung ương Thái Nguyên (Luận văn thạc sĩ)Đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân hội chứng mạch vành cấp được can thiệp động mạch vành qua da tại Bệnh viện Đa khoa Trung ương Thái Nguyên (Luận văn thạc sĩ)

Chuyeen ngành

: NT 62.72.20.50

N

DANH M C CH VI T T T

(American College of cardiology)

(American Diabetic Association)

AHA : H i tim m ch Hoa k

(American Heart Association)

(High density lipoprotein cholesterol)

(Left ventricular end diastolic diameter)

(Left ventricular end systolic diameter) MSCT :Ch p c t l

(Multislice computer tomography).

NMCT : Nh

NMCTSTC : Nh

NMCTKSTC : Nh

(Percutaneous coronary intervention)

M C L C

1

3

3

1.2 .8

12

1.4 26

1.5 27

: 30

30

31

31

31

33

45

46 47

47

50

50

50

59

64

64

71 771

782

79 80

81

DANH M

i 4 6

41

DANH M C BI U

50

54 58

60 63

DANH M C B NG

11

16

( 17

17

18

18

19

B ng 1.8 Ch 23

B i ch s kh i 33

B VIII 33

B n v t ng c theo h i tim m ch Canada 34

B n v Killip b 34

B nh r i lo n chuy ESC/ESH 2013 35

B n v t c a c b nh 35

B ng 2.7 i t n su t t ACC/AHA 2013 36

B n v ng c tim 36

B t ng m 37

B ng 3.1 T l b u 48

B m v tu i, gi i c u 48

B m v ngh nghi p 49

B m v th tr ng c 49

B ng 3.5 S u t c can thi p 50

B ng c u 51

B m v m t s tri u ch ng th c th c can thi p 52

B m tr s huy n s nh i ch ng m p 52

B killip c a ng u 53

B ng 3.10 K t qu a u 53

B ng 3.11 m v nh 54

B ng 3.12 M a th n vi i lo n nh p tim 55

B ng 3.13 V ng m 55

B ng 3.14 M c t u 56

B ng 3.15 M t u 56

B ng 3.16 M t c u 57

B ng 3.17 S t c a u 57

B ng 3.18 m r i lo n v b i ch p 58

B ng 3.19 i v c c c sau can thi p 59

B ng 3.20 p c u 59

B ng 3.21 T l b i thi n v huy p 60

B ng 3.22 p 61

B ng 3.23 K t qu ki t s YTNC sau can thi p 61

B ng 3.24 S a b i ch ng p sau can thi 62

B ng 3.25 S i th a b i ch

c p sau can thi 62

gi c can thi p 63

tim [4], [52], [53], [81], [83], [85],

* (Right coronary artery-RCA)

((

-+

u [30], [36], [84].

14% (nam)(

nh cao kho ng 24 gi v ng sau 48-72 gi

*

,NMCT (

[7]

-.K-MB

I

.Trung

B 1.5 C [16]

2,44,3

1,61

trong

30 n (%)

trong n (%)

1.3.3

*

(, n

83,9%; HbA1C :

[33]

-C [75]

((

[62]

((

(Vd)

[46]

1.5.2.

[21]

.+

B ng 2 i u t t

theo ACC/AHA 2013 [84]

ngSuy tim EF b o t n

i lo n v

d, Vs theo Simpson

- i huy t , c i thi n ho i thi n

i thi n C i thi m n i v i triglycerid, cholesterol,

m ch

nghi m:

Bilan lipidHbA1C

tim

t

, NMCTKSTC ( n = 48)

NMCTKSTC ( n = 48)

NMCTSTC ( n = 25) (n=73)

CTKSTC ( n = 48)

NMCTKSTC ( n =48 )

NMCTSTC ( n =25 )

ng 3.19.

NMCTKSTC (n=48)

NMCTSTC (n=25)

p<0,05.

m MCTKSTC

(n=48)

NMCTSTC (n=25)

m

MCTKSTC (n=48)

NMCTKSTC (n=25)

(60%> 45%) [6], [74],

c

NMCT

[13]

chu

14,6%

i c a thu ng th i can thi ng m ch

c v

Theo bi s trong bilan lipid sau can thi p d u

gi t so v c can thi p c th : T l r i lo

(43,8% xu l r i lo n Triglycerid gi m t 31,5% xu ng 10,9%, t l r i lo n HDL-C gi m t 23,3% xu ng 15,1% , t l r i lo n LDL-

19,17%, theo b ng [3.22], [3.23] HbA1C sau can thi u c i thi n t t c

a HbA1C sau can thi p gi

i p<0,05 c bi t sau can thi p t l b m

c HbA1C chi m 64,3%

p<0,01 [46]

[70].Mahmoud Momtahen

[62]

[45].

(62,5%)

-,

gi can thi ng m a",Tim m ch h c Vi t Nam, 58,tr

tim", Tim m ch h c Vi t Nam, 54,tr 65-73.

u Ti ng Anh

22 ACCF/AHA (2011), Pocket guideline management of patient undergoing

coronary artery revascularization,pp 37.

23 Asaf Bitton, Thomas Gazianoet al (2010), "The Framingham Heart

",53(1),pp 68-78.

24 M D Ashen, R S Blumenthal (2005), "Clinical practice Low HDL

cholesterol levels",N Engl J Med, 353(12), pp 1252-1312.

25 Kranenburg and associates (2015), "The Relation Between HbA1c and

Cardiovascular Events in Patients With Type 2 Diabetes With and

Without Vascular Disease",Diabetes Care, pp 1-6.

26 P Barter, A M Gotto, J C LaRosa, J Maroni, M Szarek, S M Grundy,

J J Kastelein, V Bittner, J C Fruchart (2007), "HDL cholesterol, very

low levels of LDL cholesterol, and cardiovascular events",N Engl J Med, 357(13),pp 1301-1311.

27 D L Bhatt (2013), "Timely PCI for STEMI still the treatment of

choice",N Engl J Med, 368(15), pp 1446-1453.

28 Steg PG Bhatt DL, Ohman EM (2006),"International prevalence,

recognition, and treatment of cardiovascular risk factors in outpatients

with atherothrombosis",JAMA, 295,pp 180-189.

29 K Bibbins-Domingo, P Coxson, M J Pletcher, J Lightwood, L

Goldman (2007), "Adolescent overweight and future adult coronary

heart disease",N Engl J Med, 357(23),pp 2371-2380.

30 European Society of Cardiology (2013), "ESC Guidelines for the

management of acute coronary syndromes in patients presenting

31 M D Cheitlin, W F Armstrong, G P Aurigemma, G A Beller, F Z

Bierman, J L Davis (2003), "ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application

of Echocardiography)", Circulation,108(9),pp 1146-1208.

32 A V Chobanian, G L Bakris, H R Black, W C Cushman, L A Green,

J L Izzo, Jr., D W Jones, B J Materson, S Oparil, J T Wright, Jr.,

E J Roccella (2003), "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of

High Blood Pressure", JAMA, 289(19),pp 2560-2620.

33 Choi Y.J, Park J.S, Kim Ung (2013), "Changes in smoking behavior and

adherence to preventive guidelines among smokers after a heart

attack".Journal of Geriatric Cardiology, 10,pp 146-150.

34 J C Cohen, E Boerwinkle, T H Mosley, Jr., H H Hobbs (2006),

"Sequence variations in PCSK9, low LDL, and protection against

coronary heart disease", N Engl J Med, 354(12),pp 1264-1336.

35 A.warell David, M.Cox Timothy, et al (2004), Textbook of medicine 4

ed Management of acute coronary syndromes, Oxford university press,pp 1840-1854

36 E Agabiti-Rosei, M L Muiesan (2005), Hypertension& Left Ventricular

Hypertrophy, Dialogues in Cardiovascular Medicine, 10(1),pp 1-23.

37 Edoardo Mannucci,Laria Dicembrini (2013), "Is Glucose Control

Important for Prevention of Cardiovascular Disease in

Diabetes?"Diabetes Care, 36,pp 259-262.

pp 1-40.

39 A S Go, D Mozaffarian, V L Roger, E J Benjamin, J D Berry, W B

Borden, D M Bravata, S Dai, E S Ford, C S Fox, S Franco, H J Fullerton, C Gillespie, S M Hailpern, J A Heit, V J Howard, M D Huffman, B M Kissela, S J Kittner, D T Lackland, J H Lichtman,

L D Lisabeth, D Magid, G M Marcus, Marelli (2013), "Heart disease and stroke statistics 2013 update: a report from the American Heart

Association",Circulation, 127(1),pp 6-245.

40 Grigorios, T.sigkas, et al (2011), "Stent restentnosis, pathophysiology and

treatment options: A 2010 update",Hellenic J cardiol, 52,pp 149-157.

41 Guido Parodi, Nazario Carrabba, Giovanni M Santoro, Gentian Memisha

(2006), "Heart Failure and Left Ventricular Remodeling After Reperfused Acute Myocardial Infarction in Patients With

Hypertension", Hypertension, 47,pp 707-710.

42 Hesham Rashid, Hesham Abu El-Enien, Maher Ibraheem (2014), "The

Predictive Value of Tissue Doppler for Left Ventricular Recovery and Remodeling after Primary Percutaneous Coronary Intervention",

Journal of Cardiology & Current Research, 1(6),pp 1-7.

43 Hokanson et al (1998), "Hypertriglyceridemia as a Cardiovascular Risk

Factor",Am J Cardiol, 3, pp 213-219.

44 IDF (2012), "International diabetes federation, Global guideline for type 2

diabetes",Diabetes, pp 5-98.

45 (2012), "Occurrence and predictors of left

ventricular systolic dysfunct

percutaneous coronary intervention",Kardiol Pol, 70(4),pp 329-340.

function after primary angioplasty for acute myocardial

infarction",European Heart Journal, 22,pp 785-790.

47 P A James, S Oparil, B L Carter, W C Cushman, C

Dennison-Himmelfarb, J Handler, D T Lackland, M L LeFevre, T D MacKenzie, O Ogedegbe, S C Smith, Jr., L P Svetkey, S J Taler, R

R Townsend, J T Wright, Jr., A S Narva, E Ortiz (2014), "2014 Evidence-Based Guideline for the Management of High Blood Pressure

in Adults Report From the Panel Members Appointed to the Eighth

Joint National Committee (JNC 8)",JAMA, 5,pp 507-527.

48 D Berry Jarett et al (2012), "Lifetime Risks of Cardiovascular Diseasea a

meta-analysis study at the individual level using data from 18 cohort

studies involving", N Engl J Med, 366,pp 312-321.

49 Jeffrey, R.Bender et al (2011), Oxford America Handbook of Cardiology

1 ed Coronary artery disease, Oxford university express, pp 89-111

50 P Jha,R Peto (2014), "Global effects of smoking, of quitting, and of

taxing tobacco",N Engl J Med, 370(1),pp 60-68.

51 P Jha, C Ramasundarahettige, V Landsman, B Rostron, M Thun, R N

Anderson, T McAfee, R Peto (2013), "21st-century hazards of

smoking and benefits of cessation in the United States", N Engl J Med,

368(4),pp 341-391

52 Jukema et al (2012), "Restenosis after PCI Part 1: pathophysiology and

risk factors",Nat Rev Cardiol, 9,pp 53-62.

53 Kassaian et al (2012), "Glycosylated hemoglobin (HbA1c) levels and

clinical outcomes in diabetic patients following coronary artery

stenting",Cardiovascular Diabetology, 11,pp 1-10.

54 Morton Kern et al (2013), "The intervention cardiac catheterization

handbook", 3 ed, Elsevier,p 466.

ed, Risk factors for cardiovascular disease, Elsevier,pp 312-314.

56 Leonardo Bolognese et al, "Left Ventricular Remodeling After Primary

Coronary Angioplasty Patterns of Left Ventricular Dilation and

Long-Term Prognostic Implications",Circulation, 106,pp 2351-2357.

57 G N Levine et al (2011), "2011 ACCF/AHA/SCAI Guideline for

Percutaneous Coronary Intervention",Circulation, 124(23),pp 574-651.

58 G.N Levine (2011), "ACCF/AHA Guideline management of patient with

UA/NSTEMI".J Am Coll Cardiol, 58(24),pp 215-367.

59 Peter Libby (2011), "Current Concepts of the Pathogenesis of the Acute

Coronary Syndromes, Circulation, 104, pp 365-372.

60 Peter Libby (2013), "Mechanisms of Acute Coronary Syndromes and

Their Implications for Therapy", N Engl J Med, 368,pp 2004-2017.

61 Lopez et al (2013), "Guiline and Standards Recommendations for

Quantification Methods During the Performance of a Pediatric Echocardiogram: A Report From the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and

Congenital Heart Disease Council",Journal of American Society of Echocardiography, 23, pp 465-560.

62 Mahmoud Momtahen, Seifolah Abd, Zahra Ojaghi, Zahra Javady-nejad ,

Shabnam Momtahen (2007), "Global and Regional Left Ventricular Function Improvement Following Successful Percutaneous Coronary Intervention in Patients with Ischemic Left Ventricular

Dysfunction",Arch Iranian Med, 10(3),pp 387-389.

63 Giuseppe Manacia et al (2013), "ESH/ESC Guidelines for the

management of arterial hypertension",Journal of Hypertension, 31,pp

1281-1333

acute coronary syndromes in patients presenting without persistent

ST-segment elevation",European Heart Journal, 2015, pp 3-14.

65 Michael Crawford (2002), Current Diagnosis and Treatment in

Cardiology, 2 ed, Lipid disorder, MCGraw-Hill, pp 16-63.

66

Eric L Michelson (2008), "Impact of diabetes on outcomes in patients

with low and preserved ejection fraction heart failure", Eur Heart J,

29,pp 1377-1385

67 M.Gulizia Michele (2007), "Current news in Cardiology" Acute coronary

syndrome, Springer,pp 375-382

68 Moscaritolo et al (2007), "Evidence-based guidelines for cardiovascular

disease prevention in women: 2007 update",Circulation, 115(11),pp

1481-1960

69 Lung National Health and Blood Institute (2002), National Cholesterol

Education Program-NCEP ATP III, inDetection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), pp 2-128.

70 Nazario Carrabba, Renato Valenti, Guido Parodi (2004), "Left Ventricular

Remodeling and Heart Failure in Diabetic Patients Treated With

Primary Angioplasty for Acute Myocardial Infarction",Circulation,

110,pp 1974-1979

71 R.Colledge Nicki, R.Walker Brian et al (2010), Davidson's Principles &

Practice of Medicine, Diabetes Mellitus, Churchill Livingstone

Elsevier,pp 795-834

72 Paolo Palange, Anita Simonds (2010), Smoking-Related Diseases, ERS

Handbook Respiratory medicine, 1,pp 291-294

McConnachie, S Pringle, D Murdoch, F Dunn, K Oldroyd, P Macintyre, B O'Rourke, W Borland (2008), "Smoke-free legislation

and hospitalizations for acute coronary syndrome",N Engl J Med,

359(5),pp 482-573

Marcelo Rodrigues Pinto (2013), "Middle-Term Assessment of Cardiovascular Risk Factor Control in a Prospective Cohort of High-

risk Patients Treated by Percutaneous Coronary Intervention", Rev Bras Cardiol Invasiva, 21(2),pp 121-148.

75 Seyed Kianoosh Hosseini, Maryam Tahvildari, Mohammad Javad

Alemzadeh Ansari, Manouchehr Nakhjavani, Alireza Esteghamati(2013), "Clinical Lipid Control Success Rate Before and After Percutaneous Coronary Intervention in Iran; a Single Center

Study",Iranian Red Crescent Medical Journal, 15(6),pp 476-548.

76 Stampfer et al (2000), "Primary prevention of coronary heart disease in

women through diet and lifestyle",N Engl J Med, 343,pp 18-22.

77 Stampfer, Manson JE et al (1990), "A prospective story of obessity and

risk of coronary heaart disease in woman",N Engl J Med, 322, pp

882-889

78 S T Stewart, D M Cutler, A B Rosen (2009), "Forecasting the Effects

of Obesity and Smoking on U.S Life Expectancy",N Engl J Med,

361(23),pp 2252-2312

79 F Taylor, M D Huffman, A F Macedo, T H Moore, M Burke, G

Davey Smith, K Ward, S Ebrahim (2013), "Statins for the primary

prevention of cardiovascular disease", Cochrane Database Syst Rev,

pp 1654-67

Derazne, D Tzur, A Shamis, S Vinker, A Rudich (2011),

"Adolescent BMI trajectory and risk of diabetes versus coronary

disease",N Engl J Med, 364(14),pp 1315-1340.

81 Venkata, Kishore et al (2013), "Long-Term Follow Up of Percutaneous

Years of Age", Am J Cardiol, 112,pp 918-922.

82 WHO (2013), The Asia Pacific perspective: Re

treatment, pp 1-18.

83 M.J Wolk, S.R Bailey, J.U Doherty, P.S Douglas, R.C Hendel (2014),

"ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality Appropriate Use Criteria for the Detection and Risk

Assessment of Stable Ischemic Heart Disease",J Am Coll Cardiol,pp

380-406

84 Yancy et al (2013), "ACCF/AHA Guideline for the Management of Heart

Failure", Circulation, 128,pp 1810-1852.

85 S Yusuf et al (2014), "Cardiovascular Risk and Events in 17 Low-,

Middle-, and High-Income Countries",N Engl J Med, 371(9),pp

818-845

86 S Yusuf, S Hawken, S Ounpuu, T Dans, A Avezum, F Lanas, M

McQueen, A Budaj, P Pais, J Varigos, L Lisheng (2004), "Effect of potentially modifiable risk factors associated with myocardial infarction

in 52 countries (the INTERHEART study",Lancet, 364,pp 937-989.